PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 14745978

Does terbutaline damage the developing heart?

Melissa C Rhodes·Abraham Nyska·Frederic J Seidler·Theodore A Slotkin
View original source ↗Export metadata ↓

Abstract

BACKGROUND: Beta(2)-Adrenoceptor (betaAR) agonists, such as terbutaline, are widely used to arrest preterm labor. They also cross the placenta where they stimulate receptors in fetal tissues, which in turn use betaAR input for trophic control of cell replication and differentiation. METHODS: As rats are altricial, we administered terbutaline in two different postnatal exposure periods (10 mg/kg given daily on Days 2-5 or 11-14). RESULTS: Hearts were examined twenty-four hours after the last dose and on postnatal day 30 for cardiac damage. Neither treatment paradigm caused an increase in cardiac abnormalities compared to controls but quantitative analysis of the number of nuclei indicated reductions in females. CONCLUSIONS: These findings do not support earlier case reports of outright myocardial necrosis after terbutaline tocolysis in human infants. Nevertheless, the significant statistical association between terbutaline and cardiac anomalies in epidemiological studies suggest that terbutaline may sensitize the developing heart to other insults that affect development.

Explore related subjects

Adrenergic beta-AgonistsAnimalsCell NucleusFemaleHeartMyocardiumNecrosisPregnancyPregnancy, AnimalRatsReceptors, Adrenergic, betaTerbutalineTime FactorsTocolysisTocolytic AgentsJournal ArticleResearch Support, U.S. Gov't, P.H.S.

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Melissa C Rhodes, Abraham Nyska, Frederic J Seidler, Theodore A Slotkin. 2003. Does terbutaline damage the developing heart?. https://doi.org/10.1002/bdrb.10043

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Asthma: diagnosis and management.

The diagnosis and management of asthma continue to be of critical importance, as recent trends have demonstrated its increasing prevalence, morbidity, and perhaps mortality. Because current treatments for asthma are effective and safe, it is important to diagnose asthma early and to use treatments effectively, particularly those directed toward airway inflammation. The diagnostic measures and array of medications, both those currently available and on the horizon, provide an armamentarium for effective diagnosis, management, and monitoring of asthma. In the coming years, it is expected that additional testing modalities will be available for more precise monitoring of asthma control, and an increased understanding of pharmacogenetics will enable the tailoring of asthma medications to specific patients, providing customized therapy to maximize asthma control.

Adrenergic beta-Agonists↗
PubMed2006

Differential phosphorylation and dephosphorylation of beta2-adrenoceptor sites Ser262 and Ser355,356.

Activated beta2-adrenoceptors are rapidly desensitized by phosphorylation of Ser262 by protein kinase A (PKA) and of Ser355,356 by G-protein-coupled receptor kinase (GRK). We sought to determine whether the phosphorylation and subsequent dephosphorylation of these sites had similar kinetics and requirements for receptor endocytosis. The phosphorylation of the PKA and GRK sites were measured using antibodies that recognize phosphoserine 262 and phosphoserine 355,356. Endocytosis in stably transfected HEK293 cells was blocked by inducible expression of dominant-negative dynamin-1 K44A or by treatment with hypertonic sucrose. The phosphorylation of the GRK site Ser355,356 during a 10 microM isoprenaline treatment rapidly reached a steady state, and the extent of kinetics of phosphorylation were unaffected by dynamin-1 K44A expression, and minimally by hypertonic sucrose. In contrast, phosphorylation of the PKA site Ser262 during a 10 microM isoprenaline treatment peaked after 2 min and then rapidly declined, while inhibition of endocytosis enhanced and prolonged phosphorylation. Treatment with 300 pM isoprenaline, a concentration too low to provoke endocytosis, also resulted in prolonged PKA site phosphorylation. The dephosphorylation of these sites was measured after removal of agonist. Significant dephosphorylation of phosphoserines 262 and 355,356 was observed under conditions of very low endocytosis, however dephosphorylation of the GRK site was greater if antagonist was present after removal of agonist. The results indicate that the kinetics of beta2-adrenoceptor GRK and PKA site phosphorylation are distinct and differently affected by endocytosis, and that receptor dephosphorylation can occur either at the plasma membrane or in internal compartments.

Adrenergic beta-Agonists↗